Trifluridine-tipiracil (Lonsurf)
Other Medications · Approved since 2015
Description
Trifluridine-tipiracil is an oral nucleoside antimetabolite chemotherapy combination agent approved for treatment of metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The medication combines trifluridine, a thymidine-based nucleoside analog, with tipiracil hydrochloride, a thymidine phosphorylase inhibitor that enhances trifluridine bioavailability. It serves as a later-line treatment option for patients with refractory metastatic colorectal cancer who have exhausted standard chemotherapy regimens.
Mechanism of Action
Trifluridine is incorporated into DNA during replication, causing DNA dysfunction and ultimately cell death through its cytotoxic effects on rapidly dividing cancer cells. Tipiracil hydrochloride inhibits thymidine phosphorylase, the enzyme responsible for trifluridine degradation, thereby increasing and maintaining therapeutic levels of trifluridine in plasma and tumor tissues.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Lonsurf |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | Oral |
| Year Approved | 2015 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.